Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Thinks It Can Do Better With GSK’s Oncologics Than GSK Did

Executive Summary

Novartis stresses the blockbuster potential, in its hands, of three products – Votrient, Tafinlar and Mekinist – that it is acquiring from GSK as part of its narrowed focus on innovative pharmaceuticals, eye care and generics, and the divestment of vaccines, OTCs and animal health.

You may also be interested in...



Sanofi Looks To Lead In Consumer Following Trade With Boehringer Ingelheim

Sanofi will trade Merial animal health for most of Boehringer Ingelheim’s OTC drug and supplement business as both drug makers look to build critical mass in key diversified areas. Consumer healthcare is poised to become Sanofi’s second top-selling franchise after diabetes.

Sanofi Looks To Lead In Consumer Following Trade With Boehringer Ingelheim

Sanofi will trade Merial animal health for most of Boehringer Ingelheim’s OTC drug and supplement business as both drug makers look to build critical mass in key diversified areas. Consumer healthcare is poised to become Sanofi’s second top-selling franchise after diabetes.

AstraZeneca Capitalizing On Respiratory With Actavis’ Divestiture

The British pharma is acquiring Actavis’ unwanted respiratory portfolio in a deal that will help AstraZeneca meet the $8 billion in revenues it expects to achieve from its respiratory franchise by 2023. For Actavis, it means unloading a handful of drugs that were underperforming and neglected.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel